Why Did SoundHound AI Stock Go Up?
SoundHound AI (NASDAQ:SOUN) has moved higher in recent days, breaking…
Buy
70
DAWN Quote, Financials, Valuation and Earnings
Last price:
$12.33
Seasonality move
:
-27.33%
Day range:
$11.97 - $13.14
52-week range:
$5.64 - $13.53
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
9.47x
P/B ratio:
2.81x
Volume:
3.5M
Avg. volume:
2.9M
1-year change:
-0.32%
Market cap:
$1.3B
Revenue:
$131.2M
EPS (TTM):
-$1.49
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
DAWN
Day One Biopharmaceuticals, Inc.
|
$46.6M | -$0.17 | 63.79% | -47.93% | $23.56 |
|
CATX
Perspective Therapeutics, Inc.
|
$231.1K | -$0.35 | -57.02% | -40.33% | $12.3077 |
|
ELMD
Electromed, Inc.
|
$18M | -- | 11.04% | -- | $36.00 |
|
INFU
InfuSystem Holdings, Inc.
|
$36.7M | $0.05 | 8.36% | 39.86% | $14.20 |
|
IRTC
iRhythm Holdings, Inc.
|
$201.8M | $0.06 | 21.21% | -49.15% | $220.60 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
DAWN
Day One Biopharmaceuticals, Inc.
|
$12.34 | $23.56 | $1.3B | -- | $0.00 | 0% | 9.47x |
|
CATX
Perspective Therapeutics, Inc.
|
$2.6700 | $12.3077 | $198.5M | -- | $0.00 | 0% | 181.04x |
|
ELMD
Electromed, Inc.
|
$27.38 | $36.00 | $228.4M | 29.46x | $0.00 | 0% | 3.65x |
|
INFU
InfuSystem Holdings, Inc.
|
$8.65 | $14.20 | $175.9M | 33.08x | $0.00 | 0% | 1.30x |
|
IRTC
iRhythm Holdings, Inc.
|
$164.79 | $220.60 | $5.3B | -- | $0.00 | 0% | 7.45x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
DAWN
Day One Biopharmaceuticals, Inc.
|
0.64% | 0.473 | 0.4% | 8.29x |
|
CATX
Perspective Therapeutics, Inc.
|
1.35% | 3.042 | 1.3% | 8.47x |
|
ELMD
Electromed, Inc.
|
-- | 1.105 | -- | 4.58x |
|
INFU
InfuSystem Holdings, Inc.
|
30.8% | 4.042 | 11.73% | 1.35x |
|
IRTC
iRhythm Holdings, Inc.
|
85.74% | 2.412 | 13.23% | 4.47x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
DAWN
Day One Biopharmaceuticals, Inc.
|
$35.3M | -$24.3M | -30.8% | -30.98% | -60.94% | -$5.8M |
|
CATX
Perspective Therapeutics, Inc.
|
-$566K | -$27.9M | -37.13% | -37.63% | -13330.62% | -$18.3M |
|
ELMD
Electromed, Inc.
|
$13.2M | $2.7M | 18.88% | 18.89% | 15.81% | -$98K |
|
INFU
InfuSystem Holdings, Inc.
|
$20.3M | $3.8M | 6.43% | 9.93% | 10.45% | $8.4M |
|
IRTC
iRhythm Holdings, Inc.
|
$137.1M | -$4M | -6.2% | -54.18% | -2.08% | $20.1M |
Day One Biopharmaceuticals, Inc. vs. Competitors
-
Which has Higher Returns DAWN or CATX?
Perspective Therapeutics, Inc. has a net margin of -49.57% compared to Day One Biopharmaceuticals, Inc.'s net margin of -12425.36%. Day One Biopharmaceuticals, Inc.'s return on equity of -30.98% beat Perspective Therapeutics, Inc.'s return on equity of -37.63%.
Company Gross Margin Earnings Per Share Invested Capital DAWNDay One Biopharmaceuticals, Inc.88.74% -$0.19 $453.8M CATXPerspective Therapeutics, Inc.-270.81% -$0.35 $245.5M -
What do Analysts Say About DAWN or CATX?
Day One Biopharmaceuticals, Inc. has a consensus price target of $23.56, signalling upside risk potential of 90.89%. On the other hand Perspective Therapeutics, Inc. has an analysts' consensus of $12.3077 which suggests that it could grow by 360.96%. Given that Perspective Therapeutics, Inc. has higher upside potential than Day One Biopharmaceuticals, Inc., analysts believe Perspective Therapeutics, Inc. is more attractive than Day One Biopharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings DAWNDay One Biopharmaceuticals, Inc.6 1 0 CATXPerspective Therapeutics, Inc.12 1 0 -
Is DAWN or CATX More Risky?
Day One Biopharmaceuticals, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Perspective Therapeutics, Inc. has a beta of 1.182, suggesting its more volatile than the S&P 500 by 18.151%.
-
Which is a Better Dividend Stock DAWN or CATX?
Day One Biopharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Day One Biopharmaceuticals, Inc. pays -- of its earnings as a dividend. Perspective Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DAWN or CATX?
Day One Biopharmaceuticals, Inc. quarterly revenues are $39.8M, which are larger than Perspective Therapeutics, Inc. quarterly revenues of $209K. Day One Biopharmaceuticals, Inc.'s net income of -$19.7M is higher than Perspective Therapeutics, Inc.'s net income of -$26M. Notably, Day One Biopharmaceuticals, Inc.'s price-to-earnings ratio is -- while Perspective Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Day One Biopharmaceuticals, Inc. is 9.47x versus 181.04x for Perspective Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DAWNDay One Biopharmaceuticals, Inc.9.47x -- $39.8M -$19.7M CATXPerspective Therapeutics, Inc.181.04x -- $209K -$26M
-
Which has Higher Returns DAWN or ELMD?
Electromed, Inc. has a net margin of -49.57% compared to Day One Biopharmaceuticals, Inc.'s net margin of 12.65%. Day One Biopharmaceuticals, Inc.'s return on equity of -30.98% beat Electromed, Inc.'s return on equity of 18.89%.
Company Gross Margin Earnings Per Share Invested Capital DAWNDay One Biopharmaceuticals, Inc.88.74% -$0.19 $453.8M ELMDElectromed, Inc.78.15% $0.25 $44.7M -
What do Analysts Say About DAWN or ELMD?
Day One Biopharmaceuticals, Inc. has a consensus price target of $23.56, signalling upside risk potential of 90.89%. On the other hand Electromed, Inc. has an analysts' consensus of $36.00 which suggests that it could grow by 31.48%. Given that Day One Biopharmaceuticals, Inc. has higher upside potential than Electromed, Inc., analysts believe Day One Biopharmaceuticals, Inc. is more attractive than Electromed, Inc..
Company Buy Ratings Hold Ratings Sell Ratings DAWNDay One Biopharmaceuticals, Inc.6 1 0 ELMDElectromed, Inc.4 0 0 -
Is DAWN or ELMD More Risky?
Day One Biopharmaceuticals, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Electromed, Inc. has a beta of 0.266, suggesting its less volatile than the S&P 500 by 73.442%.
-
Which is a Better Dividend Stock DAWN or ELMD?
Day One Biopharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Day One Biopharmaceuticals, Inc. pays -- of its earnings as a dividend. Electromed, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DAWN or ELMD?
Day One Biopharmaceuticals, Inc. quarterly revenues are $39.8M, which are larger than Electromed, Inc. quarterly revenues of $16.9M. Day One Biopharmaceuticals, Inc.'s net income of -$19.7M is lower than Electromed, Inc.'s net income of $2.1M. Notably, Day One Biopharmaceuticals, Inc.'s price-to-earnings ratio is -- while Electromed, Inc.'s PE ratio is 29.46x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Day One Biopharmaceuticals, Inc. is 9.47x versus 3.65x for Electromed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DAWNDay One Biopharmaceuticals, Inc.9.47x -- $39.8M -$19.7M ELMDElectromed, Inc.3.65x 29.46x $16.9M $2.1M
-
Which has Higher Returns DAWN or INFU?
InfuSystem Holdings, Inc. has a net margin of -49.57% compared to Day One Biopharmaceuticals, Inc.'s net margin of 6.19%. Day One Biopharmaceuticals, Inc.'s return on equity of -30.98% beat InfuSystem Holdings, Inc.'s return on equity of 9.93%.
Company Gross Margin Earnings Per Share Invested Capital DAWNDay One Biopharmaceuticals, Inc.88.74% -$0.19 $453.8M INFUInfuSystem Holdings, Inc.55.65% $0.11 $80.2M -
What do Analysts Say About DAWN or INFU?
Day One Biopharmaceuticals, Inc. has a consensus price target of $23.56, signalling upside risk potential of 90.89%. On the other hand InfuSystem Holdings, Inc. has an analysts' consensus of $14.20 which suggests that it could grow by 64.16%. Given that Day One Biopharmaceuticals, Inc. has higher upside potential than InfuSystem Holdings, Inc., analysts believe Day One Biopharmaceuticals, Inc. is more attractive than InfuSystem Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings DAWNDay One Biopharmaceuticals, Inc.6 1 0 INFUInfuSystem Holdings, Inc.5 0 0 -
Is DAWN or INFU More Risky?
Day One Biopharmaceuticals, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison InfuSystem Holdings, Inc. has a beta of 1.680, suggesting its more volatile than the S&P 500 by 68.01%.
-
Which is a Better Dividend Stock DAWN or INFU?
Day One Biopharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. InfuSystem Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Day One Biopharmaceuticals, Inc. pays -- of its earnings as a dividend. InfuSystem Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DAWN or INFU?
Day One Biopharmaceuticals, Inc. quarterly revenues are $39.8M, which are larger than InfuSystem Holdings, Inc. quarterly revenues of $36.5M. Day One Biopharmaceuticals, Inc.'s net income of -$19.7M is lower than InfuSystem Holdings, Inc.'s net income of $2.3M. Notably, Day One Biopharmaceuticals, Inc.'s price-to-earnings ratio is -- while InfuSystem Holdings, Inc.'s PE ratio is 33.08x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Day One Biopharmaceuticals, Inc. is 9.47x versus 1.30x for InfuSystem Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DAWNDay One Biopharmaceuticals, Inc.9.47x -- $39.8M -$19.7M INFUInfuSystem Holdings, Inc.1.30x 33.08x $36.5M $2.3M
-
Which has Higher Returns DAWN or IRTC?
iRhythm Holdings, Inc. has a net margin of -49.57% compared to Day One Biopharmaceuticals, Inc.'s net margin of -2.7%. Day One Biopharmaceuticals, Inc.'s return on equity of -30.98% beat iRhythm Holdings, Inc.'s return on equity of -54.18%.
Company Gross Margin Earnings Per Share Invested Capital DAWNDay One Biopharmaceuticals, Inc.88.74% -$0.19 $453.8M IRTCiRhythm Holdings, Inc.71.09% -$0.16 $854.9M -
What do Analysts Say About DAWN or IRTC?
Day One Biopharmaceuticals, Inc. has a consensus price target of $23.56, signalling upside risk potential of 90.89%. On the other hand iRhythm Holdings, Inc. has an analysts' consensus of $220.60 which suggests that it could grow by 33.87%. Given that Day One Biopharmaceuticals, Inc. has higher upside potential than iRhythm Holdings, Inc., analysts believe Day One Biopharmaceuticals, Inc. is more attractive than iRhythm Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings DAWNDay One Biopharmaceuticals, Inc.6 1 0 IRTCiRhythm Holdings, Inc.12 1 0 -
Is DAWN or IRTC More Risky?
Day One Biopharmaceuticals, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison iRhythm Holdings, Inc. has a beta of 1.121, suggesting its more volatile than the S&P 500 by 12.075%.
-
Which is a Better Dividend Stock DAWN or IRTC?
Day One Biopharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. iRhythm Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Day One Biopharmaceuticals, Inc. pays -- of its earnings as a dividend. iRhythm Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DAWN or IRTC?
Day One Biopharmaceuticals, Inc. quarterly revenues are $39.8M, which are smaller than iRhythm Holdings, Inc. quarterly revenues of $192.9M. Day One Biopharmaceuticals, Inc.'s net income of -$19.7M is lower than iRhythm Holdings, Inc.'s net income of -$5.2M. Notably, Day One Biopharmaceuticals, Inc.'s price-to-earnings ratio is -- while iRhythm Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Day One Biopharmaceuticals, Inc. is 9.47x versus 7.45x for iRhythm Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DAWNDay One Biopharmaceuticals, Inc.9.47x -- $39.8M -$19.7M IRTCiRhythm Holdings, Inc.7.45x -- $192.9M -$5.2M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Goldman Sachs Going to Go Up?
Shares of financial giant Goldman Sachs (NYSE:GS) have soared by…
How High Will MSTR Stock Go?
After several months of pressure, shares of Bitcoin treasury Strategy…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Sell
48
Is GOOGL Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Alerts
Buy
59
RGC alert for Jan 23
Regencell Bioscience Holdings Ltd. [RGC] is up 40.39% over the past day.
Buy
70
BNR alert for Jan 23
Burning Rock Biotech Ltd. [BNR] is up 33.29% over the past day.
Buy
76
HYMC alert for Jan 23
Hycroft Mining Holding Corp. [HYMC] is up 17.39% over the past day.
